An FDA chemist and his son were charged yesterday with using inside info to reap $2.27 million profit in illegal trades based on drug approvals.

Cheng Yi Liang and his son Andrew used several brokerage accounts for the swindle, including $1 million off the FDA’s OK of Vanda Pharmaceutical’s Fanapt, the DOJ said.

Also yesterday, the SEC accused the two of grabbing $3.6 million via illegal trading in advance of at least 27 public reports.